Dynavax to Present at the William Blair 38th Annual Growth Stock Conference
June 11 2018 - 6:30AM
Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that
Michael Ostrach, Dynavax’s Chief Financial Officer, will present at
the William Blair 38th Annual Growth Stock Conference in Chicago,
IL. The presentation will be webcast live and will occur on
Tuesday, June 12, 2018 at 2:10 p.m. CT.
The live and replayed versions of the webcast will be available
on the “Events and Presentations” section of the Dynavax website at
http://investors.dynavax.com/events-presentations.
About Dynavax
Dynavax is a fully-integrated biopharmaceutical company focused
on leveraging the power of the body's innate and adaptive immune
responses through toll-like receptor (TLR) stimulation. Dynavax
discovers and develops novel vaccines and immuno-oncology
therapeutics. The Company’s first commercial product, HEPLISAV-B®
[Hepatitis B Vaccine (Recombinant), Adjuvanted], was approved by
the United States Food and Drug Administration in November 2017 for
prevention of infection caused by all known subtypes of hepatitis B
virus in adults age 18 years and older. Dynavax's lead
immunotherapy product, SD-101, is an investigational cancer
immunotherapeutic currently being evaluated in Phase 1/2 studies
and its second cancer immunotherapeutic, DV281, is in Phase 1
development. For more information, visit www.dynavax.com.
About HEPLISAV-BHEPLISAV-B is an adult
hepatitis B vaccine that combines hepatitis B surface antigen with
Dynavax’s proprietary Toll-like Receptor (TLR) 9 agonist to enhance
the immune response. Dynavax has worldwide commercial rights to
HEPLISAV-B.
Indication and Use HEPLISAV-B is indicated for
prevention of infection caused by all known subtypes of hepatitis B
virus in adults age 18 years and older.
Important Safety Information (ISI)Do not
administer HEPLISAV-B to individuals with a history of severe
allergic reaction (e.g., anaphylaxis) after a previous dose of any
hepatitis B vaccine or to any component of HEPLISAV-B, including
yeast.
Appropriate medical treatment and supervision must be available
to manage possible anaphylactic reactions following administration
of HEPLISAV-B.
Immunocompromised persons, including individuals receiving
immunosuppressant therapy, may have a diminished immune response to
HEPLISAV-B.
Hepatitis B has a long incubation period. HEPLISAV-B may not
prevent hepatitis B infection in individuals who have an
unrecognized hepatitis B infection at the time of vaccine
administration.
The most common patient reported adverse reactions reported
within 7 days of vaccination were injection site pain (23% to 39%),
fatigue (11% to 17%) and headache (8% to 17%).
For full Prescribing Information for
HEPLISAV-B, click here.
Contact:
David BurkeDirector, Investor Relations & Corporate
Communications510.665.7269dburke@dynavax.com
US-18-01-00113
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Apr 2023 to Apr 2024